At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 263 enrolled
Drug / intervention
Fimasartan/HCTZ combination +1 moredrug
Likely dose
Fimasartan/HCTZ combination 12.5mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
In the news
5 articles- Tango plans Phase 3 pancreatic cancer study after combo successEndpoints News·2026-06-08
- #ADA26: 19% of Phase 3 patients quit Boehringer obesity shot over side effectsEndpoints News·2026-06-07
- Innovent declares Phase 3 success for ADC that attracted huge Takeda dealEndpoints News·2026-06-05
- Otsuka energizes IgA neuropathy space with new Phase 3 Voyxact dataBioSpace·2026-06-05
- <a href="https://www.fiercebiotech.com/biotech/ada-boehringer-points-survodutides-targeted-weight-loss-tolerability-questions-linger" hreflang="en">ADA: Boehringer execs claim survodutide tolerability 'consistent' with class despite phase 3 update</a>FierceBiotech
Matched to this trial by ClinicalIndexfrom reputable biotech & medical press.
A Randomized, Double-blind, Multicenter Clinical Study to Evaluate Efficacy and Safety of Fimasartan/Hydrochlorothiazide Combination-therapy in Comparison With Fimasartan Monotherapy for Essential Hypertension Patients Not Controlled by Fimasartan 60mg(Phase 3)
In Brief
A Phase 3 clinical trial evaluating Fimasartan/HCTZ combination and Fimasartan for Essential Hypertension. Completed, enrolled 263 participants across 1 site.
Detailed Summary
The purpose of this study is to evaluate the antihypertensive efficacy and safety of Fimasartan/Hydrochlorothiazide combination 60/12.5mg\~120/12.5mg in patients with essential hypertension who are not controlled by fimasartan 60mg.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsEssential Hypertension
CountriesSouth Korea
CollaboratorsSeoul National University Hospital, The Catholic University of Korea, Korea University Guro Hospital, DongGuk University, Seoul National University Bundang Hospital, Samsung Medical Center, Asan Medical Center, Gangnam Severance Hospital, Severance Hospital, Ajou University, Chonbuk National University Hospital, Cheil General Hospital and Women's Healthcare Center, Chonnam National University Hospital, Hanyang University Guri Hospital, Yonsei University, Ilsan-Paik Hospital, SMG-SNU Boramae Medical Center, Kyung Hee University Hospital
Timeline
Phase 3CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
Enrollment StartNov 2010
First PostedDec 2010
Primary CompletionDec 2011
TodayJul 2026
First PostedDec 13, 2010
Enrollment StartNov 1, 2010
Primary CompletionDec 1, 2011
TodayJul 2, 2026
Enrollment to primary: 1.1 yearsPosted 15.6 years ago
Interventions
Fimasartan/HCTZ combinationdrug
Fimasartan/HCTZ combination 60/12.5mg 120/12.5mg
Fimasartandrug
Fimasartan 60mg, 120mg